Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Therapy related core binding factor Acute Myeloid Leukemia (CBF-AML) responds favorably to fludarabine, cytarabine, GCSF (FLAG) based therapy: Exploratory Analysis from a Phase 2 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJayastu SenapatiNPNaveen PemmarajuAQAndres Quesada

Discussion

Loading...

Member takes

Overview

Exploratory analysis shows FLAG therapy provides similar survival in therapy related CBF-AML and de novo CBF-AML, suggesting effective treatment alternatives.

Key Points

  • Among patients with therapy related CBF-AML, FLAG therapy yielded comparable overall survival to de novo CBF-AML.
  • The optimal PCR response rate post-induction was 41%, with higher rates in those treated with gemtuzumab ozogamicin.
  • This analysis was part of an ongoing phase 2 clinical trial investigating treatment efficacy in adult CBF-AML patients.
  • These findings highlight the potential of FLAG therapy in achieving equivalent outcomes across different CBF-AML subtypes.

Cite This Study

Senapati et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0a3https://doi.org/10.1182/blood-2025-1724
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1FLAG-IDA as frontline induction improves outcomes in pediatric patients with core-binding factor or KMT2A-rearranged acute myeloid leukemia: A multicenter cohort study in southern China2025 · 1 citations
  2. 2Therapy-related core binding factor Acute Myeloid Leukemia – a Study of the french acute leukemia intergroup2025
  3. 3Efficacy and safety of FLAG and CLAG regimens (Replacing Cyclophosphamide) in conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory malignant hematologic diseases2025
  4. 4Initial results from a phase 2 study of cladribine, cytarabine, and granulocyte-colony stimulating factor with gemtuzumab ozogamicin (CLAG-GO) for the treatment of patients with relapsed/refractory acute myeloid leukemia2025
  5. 5FLAG-mitoxantrone combined with low-dose venetoclax (7 Days): A highly efficient regimen and excellent bridge for allogeneic hematopoietic transplant for newly diagnosed and relapsed/refractory AML.2025